LifeArc
LifeArc is a self-funded UK medical research charity that translates science into treatments for rare diseases, motor neuron disease, childhood cancer, respiratory disease, and global health, offering antibody humanisation, drug discovery, diagnostics, clinical, and data science services backed by a £1.255bn investment portfolio.
- Company typePrivate
- Founded1992
- HeadquartersLondon, United Kingdom
- Headcount251–500
- GTM typeB2B
- OfferingServices
What LifeArc does
LifeArc is an independent, self-funded not-for-profit medical research charity headquartered in London with research facilities in Edinburgh and Stevenage. Operating since 1992 (originally MRC Technology, rebranded in 2017), LifeArc focuses on translational science for diseases where commercial incentives are insufficient, principally rare diseases, motor neuron disease and rare dementias, chronic and rare respiratory disease, childhood cancer, and global health threats including antimicrobial resistance.
The organisation runs five core scientific platforms: antibody humanisation and discovery (using its proprietary Kymouse transgenic platform and single B-cell technologies, with a 30-year track record including contributions to Keytruda), small molecule drug discovery including PROTACs and E3 ligase-based targeted protein degradation, ISO 13485-certified diagnostics development, clinical development support, and data science spanning cheminformatics, bioinformatics, and AI/ML. It also operates iPSC disease modelling for neurodegeneration and an early-stage venture investment arm (LifeArc Ventures).
LifeArc is funded primarily through returns on a £1.255bn investment portfolio (December 2024) following its 2019 royalty monetisation of Keytruda (pembrolizumab). Additional income comes from service agreements, royalties, milestones, and venture returns. The charity operates through partnerships with academia, NHS hospitals, other charities, regulators (MHRA), and industry; it does not sell products commercially and instead deploys funding, scientific expertise, and venture capital to de-risk translational programmes that it then hands off to commercial partners, spin-out companies such as RQ Bio, or new initiatives such as the integrated Rare Therapies Launch Pad for individualised medicines.
LifeArc firmographics
Firmographics- Name
- LifeArc
- Legal name
- LifeArc
- Website
- https://www.lifearc.org/
- Company type
- Private
- Founded year
- 1992
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- LifeArc is a self-funded UK medical research charity that translates science into treatments for rare diseases, motor neuron disease, childhood cancer, respiratory disease, and global health, offering antibody humanisation, drug discovery, diagnostics, clinical, and data science services backed by a £1.255bn investment portfolio.
- Ownership category
- akta.pro rank
Where LifeArc is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices4 records
Markets served
LifeArc business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales
Revenue model
- Investment Portfolio Returns: LifeArc's fundamental income source comes from their investment portfolio which stood at £1.255 billion as of December 2024. They invest in diverse asset classes including global equities, fixed-income investments, private markets, infrastructure, real estate and hedge funds, seeking to outpace UK annual wage inflation by 3.5% per year over the long term. Returns fund translational activity.
- Royalty and Milestone Payments: When collaborating on projects, LifeArc receives portions of royalty interest. In 2019, they monetized a portion of their royalty interests in the cancer medicine Keytruda (pembrolizumab). They also receive income from service agreements, royalties, and milestones.
- LifeArc Ventures Investment Returns: LifeArc Ventures invests in early-stage science-led companies, providing seed and series A investments with scientific support through expert scientists and labs. Financial returns from investments are returned to LifeArc to further its charitable goals.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels10 records
LifeArc product offering
Product offeringCore offering
LifeArc is a self-funded medical research charity that provides translational science services to academic, biotech, pharmaceutical, and charity partners. Its core offerings include antibody humanization and discovery using the Kymouse platform, small molecule drug discovery, diagnostics development in an ISO 13485-certified environment, clinical development support, and data science/AI capabilities. It also runs LifeArc Ventures for seed and Series A investment in early-stage life sciences companies, alongside co-funding programs (PACE, C-Further, Bio-Hermes-002, Translational Centres for Rare Disease) targeting MND, rare dementias, respiratory disease, childhood cancer, rare disease, and global health.
Product overview
LifeArc is a not-for-profit medical research organisation offering a comprehensive portfolio of translational science services across five focus areas: Motor Neuron Disease & Rare Dementias, Chronic & Rare Respiratory Disease, Rare Disease, Childhood Cancer, and Global Health. The core service offerings include Antibody Development Services (humanisation and discovery using Kymouse platform), Clinical Development Support, Data Science Services, Diagnostics Development (ISO 13485-certified), and Small Molecule Drug Discovery. LifeArc Ventures provides early-stage investment and scientific support to biotech companies. The organisation also operates major partnership-enabled initiatives including the C-Further Consortium for paediatric oncology, PACE for antimicrobial resistance, Bio-Hermes-002 for Alzheimer's diagnostics, and the LifeArc Translational Centres for Rare Disease. Additional offerings include the Rare Therapies Launch Pad for individualised medicines and various patient engagement programmes such as the MND Insights Group.
Differentiator
Problem solved
Functional benefit
Brands
- LifeArc Ventures: Early-stage venture investment arm that invests in science-led companies in therapeutics, HealthTech and medical devices.
- MRC Technology (former name)
Products and services
- Antibody Development Services Advanced antibody humanisation and discovery services for academic, biotech, and pharma partners, leveraging the proprietary Kymouse transgenic platform and single B-cell technologies to generate fully human therapeutic monoclonal antibodies.
- Clinical Development Support Bespoke clinical development strategies and planning support for partners, covering clinical affairs, trial design and operations, regulatory compliance, and patient and healthcare professional engagement.
- Data Science Services Data science team providing cheminformatics, computational chemistry, bioinformatics, clinical and health data analysis, data engineering, and AI/ML capabilities for drug discovery and clinical pathways, including gold-standard iPSC models for neurodegeneration.
- Diagnostics Development Services Comprehensive diagnostic development support from assay design through clinical validation, operating in an ISO 13485-certified development environment with regulatory mapping and commercial partner facilitation.
- Small Molecule Drug Discovery State-of-the-art small molecule drug discovery service in Stevenage providing medicinal chemistry, assay development, structural biology, in silico screening, and targeted protein degradation capabilities including PROTACs and E3 ligases.
- LifeArc Ventures Early-stage life science investment arm providing seed and Series A funding to science-led companies, with scientific support through LifeArc's expert scientists and labs in Stevenage and Edinburgh.
Quantifiable outcome
- 5 licensed medicines from humanized antibodies including Keytruda
- +4 more outcomes
Companies that use LifeArc
Customer profileNamed customers8 records
Segments8 records
Ideal customer profiles3 records
LifeArc technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
LifeArc partnerships and signals
Strategic signalPartnerships
28 partnerships are on record, tiered core and major.
- RQ BiocoreLifeArc co-founded and backed RQ Bio, a UK biotech company developing long-acting antibody RQB01 for influenza prevention. LifeArc provided early investment, strategic support, initial start-up facilities, and drug discovery expertise including CMC de-risking and antibody engineering. RQ Bio secured $115 million (£85.5 million) Series A financing.
- Rare Disease ConsortiumcoreMHRA partnership with Rare Disease Consortium comprising patients, academics, industry and healthcare partners to develop new regulatory framework for rare disease therapies.
- Elpida TherapeuticscoreLifeArc partnered with Elpida Therapeutics to support development of three gene therapy programs targeting ultra-rare neurodegenerative conditions in children, including SPG50, CLN7 Batten disease, and CMT4J. LifeArc provides clinical, translational, and regulatory expertise alongside financial support, focusing on UK and Europe, aiming to create a blueprint for developing rare disease therapies.
- Bill & Melinda Gates FoundationcoreLifeArc and Gates Foundation awarded funding to seven new projects focused on reducing costs of manufacturing monoclonal antibodies from over $50-100 per gram to below $10, enhancing accessibility in resource-limited settings.
- ALS Therapy Development Institute (ALS TDI)coreLifeArc, ALS TDI, and Axol Bioscience launched the PRISM initiative to develop diverse patient-derived stem cell models for ALS/MND research, aiming to improve understanding of disease mechanisms and therapeutic development.
- C-Further ConsortiumcoreInternational consortium dedicated to childhood cancer therapeutics with $40 million (£30 million) initial budget. Core partners include Cancer Research Horizons, LifeArc, and Great Ormond Street Hospital Charity. First programs include CF-012 for Ewing sarcoma and CF-033 for multiple children's cancers.
- Cancer Research HorizonscoreCore partner in C-Further Consortium advancing innovative cancer therapies for children and young people.
- Great Ormond Street Hospital CharitycoreCore partner in C-Further Consortium advancing innovative cancer therapies for children with initial $40 million budget.
- Global Alzheimer's Platform FoundationcoreLifeArc and GAP co-lead the Bio-Hermes-002 study testing a finger-prick blood test for Alzheimer's diagnosis. The international clinical trial involves 1,000 volunteers aged over 60 across UK, US and Canada, analyzing biomarkers including phosphorylated tau 217, GFAP, and Neurofilament light polypeptide.
- UK Dementia Research InstitutecorePartner with LifeArc and Global Alzheimer's Platform Foundation on Bio-Hermes-002 study for Alzheimer's diagnostic test.
- Genomics EnglandcoreFounding partner of Rare Therapies Launch Pad, a UK-led multi-stakeholder initiative to accelerate development and delivery of individualised medicines for rare diseases.
- Association of the British Pharmaceutical IndustrycoreFounding partner of Rare Therapies Launch Pad alongside Genomics England, universities, hospitals and patient foundations.
- Mila's Miracle FoundationcoreFounding partner of Rare Therapies Launch Pad, focused on advancing individualised medicines for rare diseases.
- NHS Blood and TransplantcoreManufacturing support for CTLA-4 insufficiency gene therapy through NHSBT's Clinical Biotechnology Centre, part of Innovation Hubs for Gene Therapies network.
- University College London (UCL)coreDeveloping first-of-its-kind gene therapy for CTLA-4 insufficiency with scientists at UCL, with clinical trial planned for 2028.
- Oxford PharmaGenesismajorLifeArc and Oxford PharmaGenesis established the MND Insights Group in 2024 to integrate lived experience of MND into research funding and design decisions, convening patients and bereaved caregivers over 1.5 years.
- Motor Neuron Disease AssociationcoreLifeArc, MND Association, and My Name'5 Doddie Foundation awarded £1 million to researchers at UCL to develop gene and cell therapies for motor neuron disease, aiming to slow disease progression and restore muscle function.
- My Name'5 Doddie FoundationcoreJoint £1 million grant with LifeArc and MND Association to UCL researchers for MND gene and cell therapy development.
- Dementia ConsortiummajorLifeArc joined drug discovery collaboration with Alzheimer's Research UK in 2013 to advance dementia research.
- UK Dementia Research Institute (UK DRI)core£30 million partnership with UK DRI to accelerate development of new diagnostic tests, treatments, and devices for people with dementia.
- Our Future HealthcorePartnership to use health data expertise to uncover insights into disease progression, stratify patient groups and accelerate clinical trials.
- Great Ormond Street Hospital (GOSH)coreCollaboration on KidsRare initiative to safely connect paediatric rare disease health data - a first-of-its-kind UK health data initiative.
- Cystic Fibrosis Trustcore£15 million partnership over 5 years to establish collaborative network of 4 research hubs accelerating development of new diagnostics and therapeutics for lung infections in cystic fibrosis.
- Innovate UKcorePACE (Pathways to Antimicrobial Clinical Efficacy) - £30 million collaborative initiative with Innovate UK and Medicines Discovery Catapult to tackle antimicrobial resistance.
- Medicines Discovery CatapultcorePACE initiative partner driving new developments to tackle antimicrobial resistance.
- Liverpool School of Tropical MedicinecorePartnership with LSTM to launch £2.7 million Translational Development Fund through the Infection Innovation Consortium (iiCON).
- Francis Crick InstitutecorePartnership with Crick Africa Network providing £7.5 million towards community science programmes in Africa.
- KisoJi BiotechnologymajorLifeArc humanized the first unconjugated antibody against TROP-2 for KisoJi Biotechnology, advancing it into clinical development.
Scale indicators16 records
Recent moves9 records
Expansion highlights8 records
LifeArc competitors and assessment
Company assessmentBroad incumbents
- Wellcome Trust: Largest UK biomedical charity with multi-billion pound endowment funding translational and basic research globally. Comparable self-funded charitable model, broader scope but similar patient-impact mission and capability to deploy substantial capital into translational partnerships.
- Howard Hughes Medical Institute (HHMI): US biomedical research organization with $20B+ endowment funding investigator-initiated research and translational science. Closest international parallel to LifeArc's model of endowment-funded scientific activity focused on patient impact.
- Medical Research Council (MRC): UK government-funded research council that LifeArc originated from. Comparable mission of funding translational biomedical research, though MRC operates as a grant-making body rather than conducting science directly.
Regional players
- Innovate UK: UK government innovation agency co-funding LifeArc's PACE initiative. Comparable funder of translational and commercial R&D in the UK life sciences sector with overlapping target beneficiaries.
Direct peers
- Cystic Fibrosis Foundation: US patient-driven charity funding CF therapeutics and translational research, with venture-style royalty monetization (Vertex partnership). Active LifeArc partner in CF translational hubs (£15M over 5 years) and structurally similar charitable translational model.
- Medicines Discovery Catapult: UK non-profit supporting drug discovery innovation with public funding. Direct peer and consortium partner (PACE) with overlapping capabilities in translational support services and shared focus on antimicrobial resistance.
- Francis Crick Institute: UK biomedical discovery institute where LifeArc hosts a partnership team. Comparable mission of advancing fundamental research toward patient benefit and operates in close geographic/scientific proximity in London's translational ecosystem.
- Cancer Research Horizons: The commercial arm of Cancer Research UK, performing translational drug discovery and development. Direct peer and consortium partner (C-Further) given shared model of charity-funded translational science, antibody/diagnostic development services, and venture-style investments in oncology.
- Harrington Discovery Institute: US-based non-profit accelerating drug discovery from academic labs via funding, scientific support, and venture creation. Closest US analogue to LifeArc's translational charity model, particularly for rare diseases.
Emerging players
- Bill & Melinda Gates Foundation: Massive philanthropic foundation funding global health innovation including LifeArc's mAb manufacturing cost-reduction projects. Comparable mission in addressing translational gaps, particularly for infectious diseases in resource-limited settings, and active co-funder.
Market position
Strengths5 records
Weaknesses2 records
Competitive moat6 records
Key risks6 records
Key highlights6 records
Customer concentration
LifeArc social profiles
Digital presenceLifeArc compliance and trust
Trust signalCompliance2 records
LifeArc financial estimates
Financial estimateRevenue estimate
Valuation estimate
LifeArc leadership team
Management profileNumber of profiles
Profiles23 records
LifeArc subsidiaries and ownership
Company hierarchySubsidiaries2 records
LifeArc funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
LifeArc M&A and investment
M&A and investmentM&A
Investments18 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about LifeArc
What does LifeArc do?
LifeArc is a self-funded medical research charity that provides translational science services to academic, biotech, pharmaceutical, and charity partners. Its core offerings include antibody humanization and discovery using the Kymouse platform, small molecule drug discovery, diagnostics development in an ISO 13485-certified environment, clinical development support, and data science/AI capabilities. It also runs LifeArc Ventures for seed and Series A investment in early-stage life sciences companies, alongside co-funding programs (PACE, C-Further, Bio-Hermes-002, Translational Centres for Rare Disease) targeting MND, rare dementias, respiratory disease, childhood cancer, rare disease, and global health.
Is LifeArc a public or private company?
LifeArc is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was LifeArc founded?
LifeArc was founded in 1992. It employs 251 to 500 people.
Where is LifeArc based?
LifeArc is headquartered in London, United Kingdom, in the Europe region.
How does LifeArc make money?
Three revenue lines are on record. Investment Portfolio Returns are the primary driver. The others are royalty and Milestone Payments and lifeArc Ventures Investment Returns.
Who are LifeArc's main competitors?
Broad incumbents on record are Wellcome Trust, Howard Hughes Medical Institute (HHMI) and Medical Research Council (MRC). Innovate UK is listed as a regional player. Direct peers are Cystic Fibrosis Foundation, Medicines Discovery Catapult, Francis Crick Institute, Cancer Research Horizons and Harrington Discovery Institute. Bill & Melinda Gates Foundation is listed as an emerging player.
Does LifeArc have an API?
No public API is recorded for LifeArc.